|
2017 Journal Article The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphomaKeane, Colm, Gould, Clare, Jones, Kimberley, Hamm, David, Talaulikar, Dipti, Ellis, Jonathan, Vari, Frank, Birch, Simone, Han, Erica, Wood, Peter, Le-Cao, Kim-Anh, Green, Michael R., Crooks, Pauline, Jain, Sanjiv, Tobin, Josh, Steptoe, Raymond J. and Gandhi, Maher K. (2017). The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma. Clinical Cancer Research, 23 (7), 1820-1828. doi: 10.1158/1078-0432.CCR-16-1576 |
|
2017 Journal Article Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Hertzberg, Mark, Gandhi, Maher K. , Trotman, Judith, Butcher, Belinda, Taper, John, Johnston, Amanda, Gill, Devinder, Ho, Shir-Jing, Cull, Gavin, Fay, Ketih, Chong, Geoff, Grigg, Andrew, Lewis, Ian D. , Milliken, Sam, Renwick, William, Hahn, Uwe, Filshie, Robin, Kannourakis, George, Watson, Anne-Marie, Warburton, Pauline, Wirth, Andrew, Seymour, John F. , Hofman, Michael S. and Hicks, Rodney J. (2017). Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102 (2), 356-363. doi: 10.3324/haematol.2016.154039 |
|
2017 Conference Publication The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical TrialShanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. |
|
2017 Conference Publication The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLDGandhi, Maher K., Keane, Colm, Tobin, Joshua W. D., Talaulikar, Dipti, Jain, Sanjiv, Vari, Frank, Kruze, Lutz, Murigneux, Valentine, Fink, Lynn, Gunawardana, Jithendra, Gould, Clare, Oey, Harold, Fink, Susanne, Trappe, Ralf Ulrich, Mathews, Marina, Francis, Santiyagu and Hoang, Thanh (2017). The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA, United States, 9-12 December 2017. Washington, DC, United States: American Society of Hematology. |
|
2017 Conference Publication Prognostic role of antitumor immunity within tumor microenvironment in follicular lymphomaYoo, H., Tobin, J., Palmatier, L., Gandhi, M. and Li, L. (2017). Prognostic role of antitumor immunity within tumor microenvironment in follicular lymphoma. Southern Regional Meeting of the American Federation for Medical Research (AFMR), New Orleans, LA, United States, 11-13 February 2017. London, United Kingdom: BMJ Group. doi: 10.1136/jim-2016-000393.429 |
|
2016 Journal Article Dielectrophoretic microfluidic chip enables single-cell measurements for multidrug resistance in heterogeneous acute myeloid leukemia patient samplesKhamenehfar, Avid, Gandhi, Maher K., Chen, Yuchun, Hogge, Donna E. and Li, Paul C. H. (2016). Dielectrophoretic microfluidic chip enables single-cell measurements for multidrug resistance in heterogeneous acute myeloid leukemia patient samples. Analytical Chemistry, 88 (11), 5680-5688. doi: 10.1021/acs.analchem.5b04446 |
|
2016 Journal Article Recent treatment advances in Hodgkin Lymphoma: a concise reviewArulogun, Suzanne, Hertzberg, Mark and Gandhi, Maher K. (2016). Recent treatment advances in Hodgkin Lymphoma: a concise review. Internal Medicine Journal, 46 (12), 1364-1369. doi: 10.1111/imj.13051 |
|
2016 Journal Article The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphomaJones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R. and Gandhi, M. K. (2016). The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 183 (2), 206-220. doi: 10.1111/cei.12716 |
|
2016 Conference Publication The IRE1/XBP1) pathway is a critical regulatory hub for human NK-cell mediated lysis and motility that modulates the actin-binding protein XIRP1Gandhi, M. K., Mujaj, S., Vari, F., Cui, Q., Nourse, J. P., Han, E. and Cristino, A. (2016). The IRE1/XBP1) pathway is a critical regulatory hub for human NK-cell mediated lysis and motility that modulates the actin-binding protein XIRP1. International Congress of Immunology (ICI), Melbourne Australia, 21-26 August 2016. Hoboken, NJ United States: Wiley-Blackwell Publishing. |
|
2016 Journal Article Whole blood EBV-DNA: a surrogate for immune dysfunction in aggressive lymphoma?Cui, Qingyan and Gandhi, Maher K. (2016). Whole blood EBV-DNA: a surrogate for immune dysfunction in aggressive lymphoma?. Leukemia and Lymphoma, 57 (3), 507-508. doi: 10.3109/10428194.2015.1087522 |
|
2016 Conference Publication A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell LymphomaGandhi, Maher K., Arpon, David, Keane, Colm, Han, Erica, Tobin, Josh, Bird, Robert, Hertzberg, Mark S., Self, Marlene, Cross, Donna, Hernandez, Annette and Vari, Frank (2016). A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego CA, United States, 3-6 December 2016. Washington, DC United States: American Society of Hematology. |
|
2016 Conference Publication Low-dose doxorubicin reduces an immunosuppressive Ly6C(lo) monocyte population to improve efficacy of anti-41BB monoclonal antibody against B cell lymphomaMckee, S. J., Doff, B. L., Gandhi, M. K. and Mattarollo, S. R. (2016). Low-dose doxorubicin reduces an immunosuppressive Ly6C(lo) monocyte population to improve efficacy of anti-41BB monoclonal antibody against B cell lymphoma. International Congress of Immunology (ICI), Melbourne, Australia, Aug 21-26, 2016. Weinheim, Germany: Wiley - V C H Verlag GmbH & Co. KGaA. doi: 10.1002/eji.201670200 |
|
2015 Journal Article Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patientsTaylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2015). Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Nephrology Dialysis Transplantation, 30 (10), 1774-1779. doi: 10.1093/ndt/gfv260 |
|
2015 Journal Article Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyKeane, Colm, Vari, Frank, Hertzberg, Mark, Le Cao, Kim-Anh, Green, Michael R., Han, Erica, Seymour, John F., Hicks, Rodney J., Gill, Devinder, Crooks, Pauline, Gould, Clare, Jones, Kimberley, Griffiths, Lyn R., Talaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology, 2 (10), e445-e455. doi: 10.1016/S2352-3026(15)00150-7 |
|
2015 Journal Article Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingKurtz, David M., Green, Michael R., Bratman, Scott V., Scherer, Florian, Liu, Chih Long, Kunder, Christian A., Takahashi, Kazuhiro, Glover, Cynthia, Keane, Colm, Kihira, Shingo, Visser, Brendan, Callahan, Jason, Kong, Katherine A., Faham, Malek, Corbelli, Karen S., Miklos, David, Advani, Ranjana H., Levy, Ronald, Hicks, Rodney J., Hertzberg, Mark, Ohgami, Robert S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125 (24), 3679-3687. doi: 10.1182/blood-2015-03-635169 |
|
2015 Journal Article HLA class I associations with EBV+ post-transplant lymphoproliferative disorderJones, Kimberley, Wockner, Leesa, Thornton, Alycia, Gottlieb, David, Ritchie, David S, Seymour, John F, Kumarasinghe, Gayathri and Gandhi, Maher K (2015). HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transplant Immunology, 32 (2), 126-130. doi: 10.1016/j.trim.2015.02.005 |
|
2015 Conference Publication Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology. |
|
2015 Conference Publication The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)Keane, Colm, Jones, Kimberly, Gould, Clare, Hamm, David, Wood, Peter, Birch, Simone, Crooks, Pauline, Green, Michael R., Taulaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL). 55th Annual Meeting and Exposition of the American-Society-of-Hematology, New Orleans, LA, United States, 7-10 December 2013. WASHINGTON: AMER SOC HEMATOLOGY. |
|
2015 Conference Publication Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after FourHertzberg, Mark S., Gandhi, Maher K., Butcher, Belinda, Columbus, Ruth, Taper, John, Trotman, Judith, Gill, Devinder, Ho, Shir-Jing, Fay, Kelth, Cull, Gavin, Grigg, Andrew P., Chong, Geoff, Lewis, Ian D., Milliken, Sam, Renwick, William, Hahn, Uwe, Filshie, Robin, Watson, Anne-Marie, Kannourakis, George, Wolf, Max, Wirth, Andrew, Warburton, Pauline Therese, Larsen, Stephen Robert, Seymour, John F. and Hicks, Rodney (2015). Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four. 57th Annual Meeting of the American Society of Hematology, Orlando, United States, Dec 05-08, 2015. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood.V126.23.815.815 |
|
2015 Journal Article Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapiesScott, Linda M. and Gandhi, Maher K. (2015). Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Reviews, 29 (6), 405-415. doi: 10.1016/j.blre.2015.06.002 |
